Key result
Epicardial obesity is linked to ~4.6-fold higher odds of preoperative RV dysfunction before mitral surgery.
Why the study?
The relationship between epicardial obesity and perioperative myocardial remodeling in patients undergoing surgical correction of mitral valve disease required assessment.
Does epicardial obesity impair perioperative and 1-year reverse myocardial remodeling in patients undergoing surgical correction of acquired non-infectious mitral valve disease?
Cohort (n=148)
Does epicardial obesity impair perioperative and 1-year reverse myocardial remodeling in patients undergoing surgical correction of acquired non-infectious mitral valve disease?
Preoperative epicardial obesity assessed by cardiac CT is associated with worse baseline cardiac chamber remodeling and blunted 1-year reverse myocardial remodeling following surgical correction of mitral valve disease.
Epicardial obesity may flag higher risk of poor remodeling after mitral valve surgery; leaves open whether CT assessment should guide management or trials.
Aim To assess the relationship between epicardial obesity (EO) and the nature of perioperative myocardial remodeling in patients undergoing surgical correction of mitral valve (MV) disease. Material and methods The study included 148 patients with acquired non-infectious MV disease who were hospitalized for surgical correction under cardiopulmonary bypass. Preoperative computed tomography (CT) of the heart was performed to assess epicardial adipose tissue (EAT) volume. Transthoracic echocardiography (Echo) with evaluation of left ventricular (LV) longitudinal myocardial strain (GLS), as well as RV systolic function (2D/3D Echo), was conducted before surgery and on postoperative day 7, day 30, and 1 year after surgery. Groups were divided based on EO presence: EO group (n=62) and no-EO group (n=86). Adipokines in blood serum were evaluated. Epicardial adipose tissue samples were taken intraoperatively, followed by an assessment of the expression of adipokine genes. Results Echo before MV correction showed that patients with EO had larger left and right atrial (LA/RA) volumes (149.0 [113.3; 209.8] vs 114.0 [97.5; 144.0] ml (p=0.03) and 96.0 [75.8; 113.3] vs 65.0 [50.0; 86.0] ml (p=0.01), respectively), and more pronounced RV systolic dysfunction (EAT volume >115.1 cm³ was associated with a 4.6-fold increase in the odds of detecting TAPSE <1.7 cm pre-MV correction [95% CI 1.254; 16.748], p=0.02). An increase of blood leptin level by 1 ng/ml is associated with a decrease in GLS LV by B - coefficient= 0.0894 (p = 0.0269) and a decrease in the RV ejection fraction by B-coefficient= -0.1488 (p = 0.0447). The expression of ADIPOQ and LEP gene had no correlation with the parameters of myocardial remodeling in patients with MV disease. In the early postoperative period, EO patients had larger atrial sizes, greater RV end-systolic volume, and worse RV/pulmonary artery coupling. One year post-MV correction, EO patients exhibited larger indexed atrial volumes and basal RV size. In the no-EO group, dynamic improvements by one year included a 10.7% increase in GLS LV (p=0.02), 33.6% reduction in indexed LA volume (p=0.004), 28% reduction in LV mass index (p=0.003), 10.3% reduction in LV end-diastolic dimension (p=0.01), 15% increase in LV stroke volume (p=0.009), 17.6% increase in TAPSE (p=0.02), and 6.5% increase in RV ejection fraction (p=0.04), which were not observed in the EO group. Conclusion The presence of epicardial obesity (verified by cardiac CT) in cardiac surgery patients with acquired non-infectious mitral valve disease is associated with less favorable remodeling of the left and right heart chambers pre-correction and less favorable reverse myocardial remodeling within one year post-surgery. A comprehensive approach identifying various obesity manifestations at the preoperative stage will allow to modify factors negatively impacting disease progression in cardiac surgery patients with MV disease.
No takes yet. Share an insight, caveat, or question.
Barbarash et al. (2026) conducted a cohort in Acquired non-infectious mitral valve disease (n=148). Epicardial obesity (epicardial adipose tissue volume >115.1 cm³) vs. No epicardial obesity was evaluated on Preoperative right ventricular systolic dysfunction (TAPSE <1.7 cm) and 1-year perioperative myocardial remodeling (OR 4.6, 95% CI 1.254-16.748, p=0.02). Epicardial obesity increased preoperative RV dysfunction odds (OR 4.6; 95% CI 1.254-16.748; p=0.02) and prevented 1-year reverse remodeling (10.7% LV GLS increase in non-obese, p=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: